Literature DB >> 8757838

Intact immune defenses are required for mice to resist the ts-4 vaccine strain of Toxoplasma gondii.

P C Sayles1, L L Johnson.   

Abstract

The ts-4 strain of Toxoplasma gondii is a temperature-sensitive mutant that fails to grow at 40 degrees C in vitro. Unlike mildly virulent cyst-forming strains, which can cause fatal chronic infections in certain mouse strains, ts-4 has been widely used to vaccinate mice against virulent T. gondii and is a valuable tool with which to investigate mechanisms of acquired resistance to this parasite. In this report, the basis for the avirulence of ts-4 is analyzed. It is shown that ts-4 is able to persist long-term in vivo in mildly immunocompromised mice, which rules out an intrinsic growth defect as a reason for avirulence. ts-4 does not induce body temperatures in mice as high as that needed to kill it in vitro. Moreover, the mild fevers elicited in resistant B6 mice are also seen in susceptible C57BL/6 scid/scid mice. However, ts-4 elicits strong preimmune defenses, dependent on gamma interferon, which are needed by mice to survive acute infection. Furthermore, CD4+ and CD8+ T-cell-dependent acquired immunity is essential for long-term survival of ts-4-infected mice.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8757838      PMCID: PMC174192          DOI: 10.1128/iai.64.8.3088-3092.1996

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  14 in total

1.  Immunization against Toxoplasma gondii.

Authors:  F G Araujo
Journal:  Parasitol Today       Date:  1994-09

2.  Synergistic role of CD4+ and CD8+ T lymphocytes in IFN-gamma production and protective immunity induced by an attenuated Toxoplasma gondii vaccine.

Authors:  R T Gazzinelli; F T Hakim; S Hieny; G M Shearer; A Sher
Journal:  J Immunol       Date:  1991-01-01       Impact factor: 5.422

3.  Temperature-sensitive mutants of Toxoplasma gondii: pathogenicity and persistence in mice.

Authors:  H Waldeland; E R Pfefferkorn; J K Frenkel
Journal:  J Parasitol       Date:  1983-02       Impact factor: 1.276

4.  Purification and further characterization of an anti-murine interferon-gamma monoclonal neutralizing antibody.

Authors:  E A Havell
Journal:  J Interferon Res       Date:  1986-10

5.  Live and killed vaccines against toxoplasmosis in mice.

Authors:  H Waldeland; J K Frenkel
Journal:  J Parasitol       Date:  1983-02       Impact factor: 1.276

6.  Multiple defects of immune cell function in mice with disrupted interferon-gamma genes.

Authors:  D K Dalton; S Pitts-Meek; S Keshav; I S Figari; A Bradley; T A Stewart
Journal:  Science       Date:  1993-03-19       Impact factor: 47.728

7.  Immunity to toxoplasmosis in hamsters.

Authors:  M R Elwell; J K Frenkel
Journal:  Am J Vet Res       Date:  1984-12       Impact factor: 1.156

8.  SCID mouse models of acute and relapsing chronic Toxoplasma gondii infections.

Authors:  L L Johnson
Journal:  Infect Immun       Date:  1992-09       Impact factor: 3.441

9.  Gamma interferon-dependent temporary resistance to acute Toxoplasma gondii infection independent of CD4+ or CD8+ lymphocytes.

Authors:  L L Johnson; F P VanderVegt; E A Havell
Journal:  Infect Immun       Date:  1993-12       Impact factor: 3.441

10.  Toxoplasma gondii possesses a superantigen activity that selectively expands murine T cell receptor V beta 5-bearing CD8+ lymphocytes.

Authors:  E Y Denkers; P Caspar; A Sher
Journal:  J Exp Med       Date:  1994-09-01       Impact factor: 14.307

View more
  11 in total

1.  Neutrophil depletion during Toxoplasma gondii infection leads to impaired immunity and lethal systemic pathology.

Authors:  S K Bliss; L C Gavrilescu; A Alcaraz; E Y Denkers
Journal:  Infect Immun       Date:  2001-08       Impact factor: 3.441

2.  The use of CpG as an adjuvant to Toxoplasma gondii vaccination.

Authors:  Jennifer A Spencer; Bruce F Smith; Anthony J Guarino; Byron L Blagburn; Henry J Baker
Journal:  Parasitol Res       Date:  2004-01-15       Impact factor: 2.289

3.  Lack of IL-15 results in the suboptimal priming of CD4+ T cell response against an intracellular parasite.

Authors:  Crescent L Combe; Magali M Moretto; Joseph D Schwartzman; Jason P Gigley; David J Bzik; Imtiaz A Khan
Journal:  Proc Natl Acad Sci U S A       Date:  2006-04-13       Impact factor: 11.205

4.  cDNA microarray analysis of host-pathogen interactions in a porcine in vitro model for Toxoplasma gondii infection.

Authors:  Margaret Okomo-Adhiambo; Craig Beattie; Anette Rink
Journal:  Infect Immun       Date:  2006-07       Impact factor: 3.441

5.  Kinetics and phenotype of vaccine-induced CD8+ T-cell responses to Toxoplasma gondii.

Authors:  Kimberly A Jordan; Emma H Wilson; Elia D Tait; Barbara A Fox; David S Roos; David J Bzik; Florence Dzierszinski; Christopher A Hunter
Journal:  Infect Immun       Date:  2009-06-15       Impact factor: 3.441

6.  Experimental ocular toxoplasmosis in genetically susceptible and resistant mice.

Authors:  Fangli Lu; Shiguang Huang; Mark S Hu; Lloyd H Kasper
Journal:  Infect Immun       Date:  2005-08       Impact factor: 3.441

7.  Establishment of tumor-associated immunity requires interaction of heat shock proteins with CD91.

Authors:  Yu Jerry Zhou; Michelle Nicole Messmer; Robert Julian Binder
Journal:  Cancer Immunol Res       Date:  2013-12-31       Impact factor: 11.151

8.  Respiratory reovirus 1/L induction of intraluminal fibrosis, a model of bronchiolitis obliterans organizing pneumonia, is dependent on T lymphocytes.

Authors:  Elizabeth I Majeski; Manjeet K Paintlia; Andrea D Lopez; Russell A Harley; Steven D London; Lucille London
Journal:  Am J Pathol       Date:  2003-10       Impact factor: 4.307

9.  Interleukin-12, dendritic cells, and the initiation of host-protective mechanisms against Toxoplasma gondii.

Authors:  L L Johnson; P C Sayles
Journal:  J Exp Med       Date:  1997-12-01       Impact factor: 14.307

10.  Identification of cellular senescence-specific genes by comparative transcriptomics.

Authors:  Taiki Nagano; Masayuki Nakano; Akio Nakashima; Kengo Onishi; Shunsuke Yamao; Masato Enari; Ushio Kikkawa; Shinji Kamada
Journal:  Sci Rep       Date:  2016-08-22       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.